Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing outcomes for the patients with extensive-stage small-cell lung cancer.

Journal of the Chinese Medical Association : JCMA·2025
Same author

Genomic insights for triple-negative breast cancer patients in Taiwan.

Journal of the Chinese Medical Association : JCMA·2025
Same author

Reward system neurodynamics during menstrual pain modulated by <i>COMT</i> Val158Met polymorphisms.

Frontiers in molecular neuroscience·2024
Same author

Neural adaptation of the reward system in primary dysmenorrhea.

Molecular pain·2024
Same author

<i>OPRM1</i> A118G polymorphism modulating motor pathway for pain adaptability in women with primary dysmenorrhea.

Frontiers in neuroscience·2023
Same author

Adaptive neuroplasticity in the default mode network contributing to absence of central sensitization in primary dysmenorrhea.

Frontiers in neuroscience·2023
Same journal

Common on "Polypoid endometriosis in a young female with systemic lupus erythematosus, mimicking ovarian and pelvic malignancy, a case report".

Taiwanese journal of obstetrics & gynecology·2026
Same journal

45,X/47,XXX at amniocentesis and detection of disomy X cell line by fluorescence in situ hybridization in uncultured amniocytes and various tissues in a pregnancy with a favorable fetal outcome and perinatal decrease of the 45,X cell line.

Taiwanese journal of obstetrics & gynecology·2026
Same journal

Low-level mosaic trisomy 21 at amniocentesis in a pregnancy associated with a favorable fetal outcome and perinatal progressive decrease of the trisomy 21 cell line.

Taiwanese journal of obstetrics & gynecology·2026
Same journal

High-level mosaic trisomy 21 at amniocentesis associated with positive NIPT for trisomy 21 in a pregnancy with postnatal decrease of the trisomy 21 cell line and a favorable fetal outcome.

Taiwanese journal of obstetrics & gynecology·2026
Same journal

Low-level mosaic trisomy 15 without UPD 15 at amniocentesis associated with cytogenetic discrepancy between uncultured amniocytes and cultured amniocytes, IUGR, preterm birth and preeclampsia in a pregnancy with a favorable fetal outcome and perinatal decrease of the trisomy 15 cell line.

Taiwanese journal of obstetrics & gynecology·2026
Same journal

Prenatal diagnosis of a familial 3p26.3p26.1 deletion in a pregnancy associated with no apparently phenotypic abnormality in the family carrier members.

Taiwanese journal of obstetrics & gynecology·2026
See all related articles

Related Experiment Videos

Chemotherapy-induced gonadotoxicity

Peng-Hui Wang, Hsiang-Tai Chao, Kuan-Chong Chao

    Taiwanese Journal of Obstetrics & Gynecology
    |May 15, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos